Live Attenuated Influenza Vaccine (Fluenz™)
- First Online:
- Cite this article as:
- Scott, L.J., Carter, N.J. & Curran, M.P. Pediatr Drugs (2012) 14: 271. doi:10.2165/11207080-000000000-00000
- 62 Downloads
Live attenuated influenza vaccine (LAIV) [Fluenz™] has a convenient intranasal route of administration. In the EU, it is indicated for the prevention of influenza disease caused by the influenza virus strains contained in the vaccine in children and adolescents aged 2 years to <18 years. The vaccine elicits a high immunogenic response, is protective against seasonal influenza infection and is associated with the development of herd immunity. LAIV is generally well tolerated, with the safety of the vaccine in the approved pediatric population generally considered to be similar to that of placebo based on clinical trials and extensive experience involving more than 39 million vaccine doses.